METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy for tough prostate cancer shows promise in early trial
Disease control CompletedThis early-phase trial tested a combination of two drugs—docetaxel (a chemotherapy) and radium 223 (a radioactive drug)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goal was to find the safest dose and wa…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Tufts Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Real-World data reveals early use of prostate cancer drug in thousands of patients
Knowledge-focused CompletedThis study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC